EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology

Charline Sommer, Sophie Jacob, Tonia Bargmann, Muhammad Shoaib, Basel Alshaikhdeeb, Venkata P Satagopam, Susann Dehmel, Vanessa Neuhaus, Armin Braun, Katherina Sewald

Clinical Immunology · 2024

DOI: 10.1016/j.clim.2024.110288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Charline Sommer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), M…. Hauptthemen laut MEDLINE: Interleukin-2, Killer Cells, Natural. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative, European Commission, European Federation of Pharmaceutical Industries and Associations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-2 (IL-2) holds promise for the treatment of cancer and autoimmune diseases, but its high-dose usage is associated with systemic immunotoxicity. Differential IL-2 receptor (IL-2R) regulation might impact function of cells upon IL-2 stimulation, possibly inducing cellular changes similar to patients with hypomorphic IL2RB mutations, presenting with multiorgan autoimmunity. Here, we show that sustained high-dose IL-2 stimulation of human lymphocytes drastically reduces IL-2Rβ surface expression especially on T cells, resulting in impaired IL-2R signaling which correlates with high IL-2Rα baseline expression. IL-2R signaling in NK cells is maintained. CD4+ T cells, especially regulatory T cells are more broadly affected than CD8+ T cells, consistent with lineage-specific differences in IL-2 responsiveness. Given the resemblance of cellular characteristics of high-dose IL-2-stimulated cells and cells from patients with IL-2Rβ defects, impact of continuous IL-2 stimulation on IL-2R signaling should be considered in the onset of clinical adverse events during IL-2 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2Killer Cells, NaturalHumansSignal TransductionPhenotypeCD8-Positive T-LymphocytesInterleukin-2 Receptor beta SubunitCD4-Positive T-LymphocytesT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

IL-2 signalingIL-2R betaImmune therapyInterleukin-2NK cellT cell

Substanzen

Interleukin-2Interleukin-2 Receptor beta Subunit

Autor:innen und Institutionen

  • Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Frau…
  • Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg.

Förderung

  • Innovative Medicines Initiative
  • European Commission
  • European Federation of Pharmaceutical Industries and Associations
  • Juvenile Diabetes Research Foundation United States of America

Zitieren

APA

Sommer, C., Jacob, S., Bargmann, T., Shoaib, M., Alshaikhdeeb, B., Satagopam, V. P., Dehmel, S., Neuhaus, V., Braun, A., & Sewald, K. (2024). Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110288

Vancouver

Sommer C, Jacob S, Bargmann T, Shoaib M, Alshaikhdeeb B, Satagopam VP, et al. Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110288

BibTeX
@article{Sommer2024,
  author = {Sommer, Charline and Jacob, Sophie and Bargmann, Tonia and Shoaib, Muhammad and Alshaikhdeeb, Basel and Satagopam, Venkata P and Dehmel, Susann and Neuhaus, Vanessa and Braun, Armin and Sewald, Katherina},
  title = {Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology},
  journal = {Clinical Immunology},
  year = {2024},
  doi = {10.1016/j.clim.2024.110288}
}
Kostenlos starten →